HROW Overview
Upcoming Projects (HROW)
-
Don’t see a project related to the company you care about? Create your own!
Executed Projects (HROW)
-
Discussing the current treatment landscape for retinal diseases, with a focus on biosimilars as Harrow obtains commercial rights to Byooviz (ranibizumab) and Opuviz (aflibercept)
Tickers: HROW, RHHBY, BIIB
Executed On: Nov 03, 2025 at 03:30 PM EST -
Discussing the potential of Harrow's BYQLOVI for Post-Operative Ocular Inflammation/Pain and OKYO Pharma's Urcosimod for Neuropathic Corneal Pain
Tickers: HROW, OKYO, Formosa Pharmacueticals
Executed On: Aug 11, 2025 at 12:45 PM EDT
Upcoming & Overdue Catalysts (HROW)
-
Don’t see a catalyst related to the company you care about? Create your own!
Strategic Initiatives (HROW)
-
Don’t see a strategic initiative related to the company you care about? Create your own!
